Atossa Therapeutics, Inc.
ATOS
$5.16
-$0.34-6.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.28M | 3.88M | 3.54M | 3.26M | 3.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.44M | 9.25M | 9.04M | 7.41M | 7.15M |
| Operating Income | -11.44M | -9.25M | -9.04M | -7.41M | -7.15M |
| Income Before Tax | -10.94M | -8.69M | -8.42M | -6.72M | -6.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.94M | -8.69M | -8.42M | -6.72M | -6.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.94M | -8.69M | -8.42M | -6.72M | -6.35M |
| EBIT | -11.44M | -9.25M | -9.04M | -7.41M | -7.15M |
| EBITDA | -11.43M | -9.25M | -9.04M | -7.41M | -7.15M |
| EPS Basic | -1.27 | -1.01 | -0.98 | -0.78 | -0.75 |
| Normalized Basic EPS | -0.79 | -0.63 | -0.61 | -0.49 | -0.47 |
| EPS Diluted | -1.27 | -1.01 | -0.98 | -0.78 | -0.75 |
| Normalized Diluted EPS | -0.79 | -0.63 | -0.61 | -0.49 | -0.47 |
| Average Basic Shares Outstanding | 8.61M | 8.61M | 8.61M | 8.61M | 8.44M |
| Average Diluted Shares Outstanding | 8.61M | 8.61M | 8.61M | 8.61M | 8.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |